VIATRIS INC. (VTRS) Operating Margin
- Operating margin · 12 months: Value -0.59%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -0.59% | Operating income / revenue. Period ending 2026-06-30. $-87.30M ÷ $14.69B × 100 ≈ -0.59% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -87.30M USD | Operating Income (Loss) |
| Revenue | 14.69B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 9.60B USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 3.98B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-87.30M | $14.69B | $9.60B | (m) | $3.98B | -0.59% |
| 2026-03-31 | $139.40M | $14.52B | $9.55B | (m) | $3.77B | 0.96% |
| 2025-12-31 | $-2.66B | $14.25B | $9.29B | (m) | $3.79B | -18.69% |
| 2025-09-30 | $-2.65B | $14.08B | $9.04B | (m) | $4.13B | -18.83% |
| 2025-06-30 | $-2.60B | $14.07B | $8.95B | (m) | $4.25B | -18.51% |
| 2025-03-31 | $-3.08B | $14.28B | $9.05B | (m) | $4.36B | -21.54% |
| 2024-12-31 | $10.10M | $14.69B | $9.12B | (m) | $4.43B | 0.07% |
| 2024-09-30 | $-264.60M | $15.00B | $9.04B | (m) | $4.98B | -1.76% |
| 2024-06-30 | $-38.80M | $15.20B | $9.00B | (m) | $5.03B | -0.26% |
| 2024-03-31 | $570.30M | $15.32B | $8.96B | (m) | $4.71B | 3.72% |
| 2023-12-31 | $766.20M | $15.39B | $8.99B | (m) | $4.65B | 4.98% |
| 2023-09-30 | $1.02B | $15.43B | $9.35B | (m) | $4.31B | 6.61% |
| 2023-06-30 | $1.13B | $15.56B | $9.43B | (m) | $4.27B | 7.25% |
| 2023-03-31 | $1.31B | $15.76B | $9.53B | (m) | $4.22B | 8.30% |
| 2022-12-31 | $1.61B | $16.22B | $9.77B | (m) | $4.18B | 9.96% |
| 2022-09-30 | $1.74B | $16.68B | $9.96B | $747.00M | $4.00B | 10.42% |
| 2022-06-30 | $1.54B | $17.14B | $10.59B | $724.20M | $4.03B | 8.96% |
| 2022-03-31 | $939.60M | $17.59B | $11.43B | $709.30M | $4.26B | 5.34% |
| 2021-12-31 | $-34.00M | $17.81B | $12.31B | $751.10M | $4.53B | -0.19% |
| 2021-09-30 | $-837.50M | (m) | $12.43B | $638.70M | $4.81B | (m) |
| 2021-06-30 | $-843.70M | (m) | $11.28B | $616.40M | $4.41B | (m) |
| 2021-03-31 | $-661.70M | (m) | $9.74B | $625.00M | $3.93B | (m) |
| 2020-12-31 | $-210.80M | $11.82B | $8.15B | $555.10M | $3.34B | -1.78% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-27 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-28 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-29 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-29 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $905.60M | $11.27B | $7.43B | $704.50M | $2.44B | 8.04% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |